Search - tctmd.com

Displaying 841 - 860 of 1179

Sort: Relevancy | Date

News Industry News

Abbott Initiates Randomized Clinical Trial in Japan to Evaluate the Absorb™ Bioresorbable Vascular Scaffold

June 11, 2013

News Daily News

African Americans’ Antiplatelet Response Handicapped by Gene Variant, ‘Race’

June 07, 2013

News Industry News

St. Jude Medical Initiates First US Clinical Study of the EnligHTN Renal Denervation System for Drug-Resistant High Blood Pressure

June 04, 2013

News Conference News EuroPCR 2013

Registry Questions Superiority of Bivalirudin Over Heparin Alone in NSTE-ACS

Yael L. Maxwell

May 23, 2013

Presentation EuroPCR 2013

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

Presenter: Sigmund Silber

May 22, 2013

News Daily News

PARADOX Published: Smokers’ Paradox Seen with Clopidogrel But not Prasugrel

Caitlin E. Cox

May 13, 2013

News Industry News

Elixir Medical Announces FDA Approval to Commence EXCELLA III Clinical Trial with DESyne® Nx Novolimus Eluting Coronary Stent System in the United States

May 08, 2013

News Daily News

GPIs Superior for Rescue Treatment after Endovascular Coiling for Cerebral Aneurysm

Caitlin E. Cox

May 03, 2013

News Daily News

ESC Offers Recommendations on Use of New Oral Anticoagulants

Yael L. Maxwell

May 03, 2013

News Daily News

Stroke After STEMI Unusual But Carries Poor Prognosis

Yael L. Maxwell

May 03, 2013

News Daily News

Los ACV tras un cuadro de STEMI son Raros pero tienen Mal Pronóstico

Yael L. Maxwell

May 03, 2013

News Industry News

Elixir Medical Corporation to Announce 6-month Results of the DESolve Fully Bioresorbable Coronary Scaffold System Pivotal Trial at Late Breaking Trial Session of EuroPCR

May 01, 2013

Presentation

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

Presenter: K. Tandjung

April 26, 2013

News Daily News

La Alta Reactividad Plaquetaria se asocia a Más Episodios Adversos tras Intervenciones Endovasculares

Yael L. Maxwell

April 26, 2013

News Daily News

High Platelet Reactivity Linked to More Adverse Events After Endovascular Procedures

Yael L. Maxwell

April 26, 2013

News Daily News

Bivalirudin Bests Heparin for Lowering Bleeding Risk After CAS

L.A. McKeown

April 26, 2013

Presentation TCTAP 2013

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Presenter: Matthew J. Price

April 24, 2013

Presentation TCTAP 2013

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Presenter: Adnan Kastrati

April 24, 2013

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Caitlin E. Cox

April 19, 2013

Advertisement

Abbott Initiates Randomized Clinical Trial in Japan to Evaluate the Absorb™ Bioresorbable Vascular Scaffold

African Americans’ Antiplatelet Response Handicapped by Gene Variant, ‘Race’

St. Jude Medical Initiates First US Clinical Study of the EnligHTN Renal Denervation System for Drug-Resistant High Blood Pressure

Registry Questions Superiority of Bivalirudin Over Heparin Alone in NSTE-ACS

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

PARADOX Published: Smokers’ Paradox Seen with Clopidogrel But not Prasugrel

Elixir Medical Announces FDA Approval to Commence EXCELLA III Clinical Trial with DESyne® Nx Novolimus Eluting Coronary Stent System in the United States

GPIs Superior for Rescue Treatment after Endovascular Coiling for Cerebral Aneurysm

ESC Offers Recommendations on Use of New Oral Anticoagulants

Stroke After STEMI Unusual But Carries Poor Prognosis

Los ACV tras un cuadro de STEMI son Raros pero tienen Mal Pronóstico

Elixir Medical Corporation to Announce 6-month Results of the DESolve Fully Bioresorbable Coronary Scaffold System Pivotal Trial at Late Breaking Trial Session of EuroPCR

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

La Alta Reactividad Plaquetaria se asocia a Más Episodios Adversos tras Intervenciones Endovasculares

High Platelet Reactivity Linked to More Adverse Events After Endovascular Procedures

Bivalirudin Bests Heparin for Lowering Bleeding Risk After CAS

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content